338 related articles for article (PubMed ID: 15908672)
1. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
Petricoin EF; Bichsel VE; Calvert VS; Espina V; Winters M; Young L; Belluco C; Trock BJ; Lippman M; Fishman DA; Sgroi DC; Munson PJ; Esserman LJ; Liotta LA
J Clin Oncol; 2005 May; 23(15):3614-21. PubMed ID: 15908672
[TBL] [Abstract][Full Text] [Related]
2. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.
Wulfkuhle JD; Edmiston KH; Liotta LA; Petricoin EF
Nat Clin Pract Oncol; 2006 May; 3(5):256-68. PubMed ID: 16683004
[TBL] [Abstract][Full Text] [Related]
3. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
Calvo KR; Liotta LA; Petricoin EF
Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
[TBL] [Abstract][Full Text] [Related]
4. Modeling of protein signaling networks in clinical proteomics.
Geho DH; Petricoin EF; Liotta LA; Araujo RP
Cold Spring Harb Symp Quant Biol; 2005; 70():517-24. PubMed ID: 16869790
[TBL] [Abstract][Full Text] [Related]
5. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer.
Gulmann C; Sheehan KM; Kay EW; Liotta LA; Petricoin EF
J Pathol; 2006 Apr; 208(5):595-606. PubMed ID: 16518808
[TBL] [Abstract][Full Text] [Related]
6. Reverse phase protein microarrays for theranostics and patient-tailored therapy.
Espina V; Wulfkuhle J; Calvert VS; Liotta LA; Petricoin EF
Methods Mol Biol; 2008; 441():113-28. PubMed ID: 18370315
[TBL] [Abstract][Full Text] [Related]
7. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy.
Speer R; Wulfkuhle J; Espina V; Aurajo R; Edmiston KH; Liotta LA; Petricoin EF
Cancer Genomics Proteomics; 2007; 4(3):157-64. PubMed ID: 17878519
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Pathology of the future: molecular profiling for targeted therapy.
Espina V; Geho D; Mehta AI; Petricoin EF; Liotta LA; Rosenblatt KP
Cancer Invest; 2005; 23(1):36-46. PubMed ID: 15779867
[TBL] [Abstract][Full Text] [Related]
10. Cancer proteomics: from biomarker discovery to signal pathway profiling.
Bichsel VE; Liotta LA; Petricoin EF
Cancer J; 2001; 7(1):69-78. PubMed ID: 11269650
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays.
Voshol H; Ehrat M; Traenkle J; Bertrand E; van Oostrum J
FEBS J; 2009 Dec; 276(23):6871-9. PubMed ID: 19860827
[TBL] [Abstract][Full Text] [Related]
12. Proteomic approaches in cancer risk and response assessment.
Petricoin EF; Liotta LA
Trends Mol Med; 2004 Feb; 10(2):59-64. PubMed ID: 15102358
[TBL] [Abstract][Full Text] [Related]
13. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.
VanMeter A; Signore M; Pierobon M; Espina V; Liotta LA; Petricoin EF
Expert Rev Mol Diagn; 2007 Sep; 7(5):625-33. PubMed ID: 17892368
[TBL] [Abstract][Full Text] [Related]
14. [Application of quantitative proteomic analysis for cancer therapy using "reverse-phase" protein lysate microarrays].
Nishizuka S; Spurrier B; Honkanen P; Austin J; Wakabayashi G
Gan To Kagaku Ryoho; 2008 Feb; 35(2):200-5. PubMed ID: 18281757
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells.
Chen YR; Juan HF; Huang HC; Huang HH; Lee YJ; Liao MY; Tseng CW; Lin LL; Chen JY; Wang MJ; Chen JH; Chen YJ
J Proteome Res; 2006 Oct; 5(10):2727-42. PubMed ID: 17022644
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms in cancer: what should clinicians know?
Ajani J; Allgood V
Semin Oncol; 2005 Dec; 32(6 Suppl 8):2-4. PubMed ID: 16360003
[TBL] [Abstract][Full Text] [Related]
17. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
McDermott U; Settleman J
J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
[TBL] [Abstract][Full Text] [Related]
18. Oncoproteomics: current trends and future perspectives.
Cho WC; Cheng CH
Expert Rev Proteomics; 2007 Jun; 4(3):401-10. PubMed ID: 17552924
[TBL] [Abstract][Full Text] [Related]
19. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT).
Sodek KL; Evangelou AI; Ignatchenko A; Agochiya M; Brown TJ; Ringuette MJ; Jurisica I; Kislinger T
Mol Biosyst; 2008 Jul; 4(7):762-73. PubMed ID: 18563251
[TBL] [Abstract][Full Text] [Related]
20. Is tailored therapy feasible in oncology?
Gasparini G; Longo R; Torino F; Gattuso D; Morabito A; Toffoli G
Crit Rev Oncol Hematol; 2006 Jan; 57(1):79-101. PubMed ID: 16337806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
